JP2016513734A - Ａｍｐｋ活性化剤及びセロトニン作動薬を含む医薬組成物並びにそれらの使用方法 - Google Patents

Ａｍｐｋ活性化剤及びセロトニン作動薬を含む医薬組成物並びにそれらの使用方法 Download PDF

Info

Publication number
JP2016513734A
JP2016513734A JP2016502780A JP2016502780A JP2016513734A JP 2016513734 A JP2016513734 A JP 2016513734A JP 2016502780 A JP2016502780 A JP 2016502780A JP 2016502780 A JP2016502780 A JP 2016502780A JP 2016513734 A JP2016513734 A JP 2016513734A
Authority
JP
Japan
Prior art keywords
acetamide
fluorobenzyl
piperidin
ethyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016502780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513734A5 (OSRAM
Inventor
ホン チェン チエン
ホン チェン チエン
Original Assignee
エーエルエス マウンテン リミテッド ライアビリティ カンパニー
エーエルエス マウンテン リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2016513734(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エーエルエス マウンテン リミテッド ライアビリティ カンパニー, エーエルエス マウンテン リミテッド ライアビリティ カンパニー filed Critical エーエルエス マウンテン リミテッド ライアビリティ カンパニー
Publication of JP2016513734A publication Critical patent/JP2016513734A/ja
Publication of JP2016513734A5 publication Critical patent/JP2016513734A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
JP2016502780A 2013-03-15 2014-03-14 Ａｍｐｋ活性化剤及びセロトニン作動薬を含む医薬組成物並びにそれらの使用方法 Pending JP2016513734A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361793407P 2013-03-15 2013-03-15
US61/793,407 2013-03-15
PCT/US2014/028413 WO2014144130A2 (en) 2013-03-15 2014-03-14 Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2016513734A true JP2016513734A (ja) 2016-05-16
JP2016513734A5 JP2016513734A5 (OSRAM) 2017-03-30

Family

ID=51538303

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502780A Pending JP2016513734A (ja) 2013-03-15 2014-03-14 Ａｍｐｋ活性化剤及びセロトニン作動薬を含む医薬組成物並びにそれらの使用方法

Country Status (16)

Country Link
US (1) US20140350064A1 (OSRAM)
EP (1) EP2983473A4 (OSRAM)
JP (1) JP2016513734A (OSRAM)
KR (1) KR20160005341A (OSRAM)
CN (1) CN105636438A (OSRAM)
AR (1) AR095631A1 (OSRAM)
AU (1) AU2014227807B2 (OSRAM)
BR (1) BR112015023922A2 (OSRAM)
CA (1) CA2909633A1 (OSRAM)
CL (1) CL2015002680A1 (OSRAM)
HK (1) HK1222297A1 (OSRAM)
IL (1) IL241587B (OSRAM)
MX (1) MX2015012760A (OSRAM)
RU (1) RU2015143438A (OSRAM)
TW (1) TW201444552A (OSRAM)
WO (1) WO2014144130A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023500493A (ja) * 2019-10-31 2023-01-06 ジェイディ・バイオサイエンス・インコーポレイテッド 三環式化合物およびその薬学的使用

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180071269A1 (en) * 2015-08-12 2018-03-15 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
ES2567105B1 (es) * 2014-09-19 2017-02-10 Consejo Superior De Investigaciones Científicas (Csic) Derivados de indol para la prevención y/o tratamiento de diabetes ytrastornos metabólicos relacionados
WO2016126662A1 (en) * 2015-02-03 2016-08-11 Kardiatonos, Inc. Compounds for the prevention and treatment of vascular disease
US10463649B2 (en) 2015-06-08 2019-11-05 Texas Tech University System Inhibitors of Mc1-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors
KR101663543B1 (ko) * 2015-07-29 2016-10-07 고려대학교 산학협력단 부스피론 유도체 및 이를 함유하는 약학 조성물
WO2017018752A1 (ko) * 2015-07-29 2017-02-02 고려대학교 산학협력단 부스피론 유도체 및 이를 함유하는 약학 조성물
EP3328494A4 (en) 2015-08-01 2019-04-03 Stephen J. Petti COMPOSITIONS AND METHODS FOR COMBINING PHARMACOLOGICAL TREATMENTS TO INDUCTION EXTENDED, Mild Acceptance of BODY CORE TEMPERATURE
CN105541665A (zh) * 2016-02-18 2016-05-04 江苏大学 一种抗肿瘤药物化合物及制备方法和应用
KR101838625B1 (ko) * 2016-09-20 2018-03-14 김브라이언 아디포넥틴 수용체에 대한 작용제 펩타이드
JP7034152B2 (ja) 2016-10-05 2022-03-11 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 小分子ａｍｐｋ活性化剤
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CN110087640A (zh) 2016-12-20 2019-08-02 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
CN107252425A (zh) * 2017-07-12 2017-10-17 上海华堇生物技术有限责任公司 去氢延胡索素的药物用途
US11723894B2 (en) * 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
US11103465B2 (en) 2017-11-22 2021-08-31 Ted's Brain Science, Inc. Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof
US11208475B1 (en) * 2018-01-30 2021-12-28 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators
CN108159044A (zh) * 2018-02-26 2018-06-15 华中科技大学 抗坏血酸与二甲双胍的复合制剂用于制备化疗药物的应用
CN112704672A (zh) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN108997172B (zh) * 2018-08-08 2020-12-15 中国人民解放军总医院 抗肿瘤化合物
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
CN109771424B (zh) * 2019-03-11 2021-03-16 马慧 一种防治老年ⅱ型糖尿病性骨质疏松症的药物组合物及其应用
CN109793727A (zh) * 2019-03-13 2019-05-24 湖北科技学院 一种有效抗恶性肿瘤的药物组合物及其应用
EP4027987A4 (en) 2019-09-10 2023-11-29 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods and materials for increasing level of phosphorylated ampk protein
CN110559298A (zh) * 2019-10-28 2019-12-13 中国药科大学 一种天然化合物Egenine用于制备抗肾纤维化药物的用途
AU2021276656A1 (en) 2020-05-19 2022-11-24 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
WO2022017440A1 (zh) * 2020-07-22 2022-01-27 山东绿叶制药有限公司 5-ht 2a受体抑制剂或反向激动剂及其制备方法和应用
TN2023000216A1 (en) 2021-03-10 2025-04-03 Jnana Therapeutics Inc Small molecule inhibitors of mammalian slc6a19 function
EP4366731A4 (en) 2021-07-07 2025-04-16 Terran Biosciences, Inc. N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDELICS AND USES THEREOF
EP4429672A4 (en) 2021-11-12 2025-04-30 Terran Biosciences Inc. PSILOCYBIN AND O-ACETYLPSILOCIN, SALTS AND SOLID FORMS THEREOF
KR20250164150A (ko) * 2022-12-05 2025-11-24 엔베다 테라퓨틱스, 인크. 장 또는 복통 치료를 위한 누트카톤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006001278A1 (ja) * 2004-06-28 2006-01-05 Kao Corporation Ａｍｐｋ活性化剤
JP2010516689A (ja) * 2007-01-16 2010-05-20 アイピントゥル，エルエルシー メタボリック症候群治療用の新規組成物
US20110281829A1 (en) * 2010-04-28 2011-11-17 Ipintl, Llc Novel composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US7754700B2 (en) * 2006-04-24 2010-07-13 Trager Seymour F Composition and methods for alleviating symptoms of neurotoxicity
US20120183600A1 (en) * 2007-01-16 2012-07-19 Chien-Hung Chen Novel composition for treating metabolic syndrome and other conditions
WO2011112167A1 (en) * 2009-03-13 2011-09-15 Reset Therapeutics, Inc. Compositions and methods for diabetes treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006001278A1 (ja) * 2004-06-28 2006-01-05 Kao Corporation Ａｍｐｋ活性化剤
JP2010516689A (ja) * 2007-01-16 2010-05-20 アイピントゥル，エルエルシー メタボリック症候群治療用の新規組成物
US20110281829A1 (en) * 2010-04-28 2011-11-17 Ipintl, Llc Novel composition

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ANISIMOV, V.N. ET AL.: ""Metformin extends life span of Her-2/neu transgenic mice and in combination with melatonin inhibits", CELL CYCLE, vol. 9, no. 1, JPN6017037382, 1 January 2010 (2010-01-01), pages 188 - 197, ISSN: 0003857251 *
BERGERON, R. ET AL.: "Effect of 5-Aminoimidazole-4-Carboxamide-1-b-D-Ribofuranoside Infusion on In Vivo Glucose and Lipid", DIABETES, vol. 50, no. 5, JPN6018031199, 2001, pages 1076 - 1082, ISSN: 0003857257 *
CARRUBA,M.O. ET AL.: "Effects of dextrofenfluramine and other anorectic drugs on experimentally induced hyperphagias", ADVANCES IN THE BIOSCIENCES(OXFORD), vol. 60, JPN6011067792, 1986, pages 353 - 60, ISSN: 0003857261 *
DAGON, Y. ET AL.: "Nutritional Status, Cognition, and Survival A NEW ROLE FOR LEPTIN AND AMP KINASE", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, no. 51, JPN6018031194, 2005, pages 42142 - 42148, ISSN: 0003857262 *
JENSEN,M.D.: "Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabol", OBESITY (SILVER SPRING), vol. Vol.14 Suppl 3, JPN7011004676, 2006, pages 143 - 149, ISSN: 0003857260 *
KADHIM, H. M. ET AL.: "Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly", JOURNAL OF PINEAL RESEARCH, vol. Vol. 41, Issue 2, JPN6018031193, 2006, pages 189 - 193, ISSN: 0003857255 *
KREJS,G.J.: "Metabolic benefits associated with sibutramine therapy", INT. J. OBES. RELAT. METAB. DISORD., vol. Vol.26 Suppl 4, JPN7011004675, 2002, pages 34 - 7, ISSN: 0003857259 *
KWON, K. J. ET AL.: "Melatonin Potentiates the Neuroprotective Properties of Resveratrol Against Beta-Amyloid-Induced Neu", JOURNAL OF CLINICAL NEUROLOGY, vol. 6, no. 3, JPN6018031191, 2010, pages 127 - 137, ISSN: 0003857254 *
KWON, K. J. ET AL.: "Melatonin synergistically increases resveratrol-induced heme oxygenase-1 expression through the inhi", JOURNAL OF PINEAL RESEARCH, vol. Vol. 50, Issue 2, JPN6018031189, 2011, pages 110 - 123, ISSN: 0003857253 *
MAN'CHEVA, T.A. ET AL.: ""Melatonin and Metformin Inhibit Skin Carcinogenesis and Lipid Peroxidation Induced by Benz(a)pyrene", BULL. EXP. BIOL. MED., vol. 151, no. 3, JPN6017037381, July 2011 (2011-07-01), pages 363 - 365, ISSN: 0003857250 *
SOLL, C. ET AL.: "Serotonin Promotes Tumor Growth in Human Hepatocellular Cancer", HEPATOLOGY, vol. Vol. 51, Issue 4, JPN6018031196, 2010, pages 1244 - 1254, ISSN: 0003857263 *
YAMAUCHI, T. ET AL: "Cloning of adiponectin receptors that mediate antidiabetic metabolic effects", NATURE, vol. 423, no. 6941, JPN6018031198, 2003, pages 762 - 769, ISSN: 0003857256 *
ZAITONE, S. ET AL.: "Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. Vol. 662, Issue 1-3, JPN6018031187, 2011, pages 70 - 77, ISSN: 0003857252 *
ZHOU, G. ET AL.: "Role of AMP-activated protein kinase in mechanism of metformin action", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 108, no. 8, JPN6018031201, 2001, pages 1167 - 74, ISSN: 0003857258 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023500493A (ja) * 2019-10-31 2023-01-06 ジェイディ・バイオサイエンス・インコーポレイテッド 三環式化合物およびその薬学的使用

Also Published As

Publication number Publication date
EP2983473A4 (en) 2016-11-23
HK1222297A1 (zh) 2017-06-30
BR112015023922A2 (pt) 2017-07-18
CA2909633A1 (en) 2014-09-18
WO2014144130A3 (en) 2015-02-05
AU2014227807A1 (en) 2015-11-05
CL2015002680A1 (es) 2016-09-02
AU2014227807B2 (en) 2018-03-08
KR20160005341A (ko) 2016-01-14
IL241587B (en) 2019-01-31
RU2015143438A (ru) 2017-04-21
WO2014144130A2 (en) 2014-09-18
MX2015012760A (es) 2016-06-17
CN105636438A (zh) 2016-06-01
TW201444552A (zh) 2014-12-01
AR095631A1 (es) 2015-10-28
EP2983473A2 (en) 2016-02-17
US20140350064A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
AU2014227807B2 (en) Pharmaceutical composition comprising an AMPK activator and a serotonergic agent and methods of use thereof
US20120183600A1 (en) Novel composition for treating metabolic syndrome and other conditions
CN101272782B (zh) 作为生长激素促分泌受体的ghrelin类似物配体的新颖的三唑衍生物
TWI556820B (zh) Ｈｓｐ９０抑制劑之組合
EP2606890A1 (en) Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
CN105163584A (zh) 用于治疗癌症的化合物
SK13952002A3 (sk) Farmaceutická kompozícia na liečenie akútnej, chronickej a/alebo neuropatickej bolesti a migrén
TW200418837A (en) Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
CN103249414A (zh) 作为生长激素促泌素受体的生长素释放肽拮抗剂的具有改善受体活性和生物利用度性质的新三唑衍生物
US20090042905A1 (en) Triazole derivatives as ligands of g-protein coupled receptors
CN119548495A (zh) (取代的1h-咪唑-4-基)(3,4,5-三甲氧基苯基)甲酮在制备治疗冠状病毒的药物中的用途
CN101495147B (zh) 药物组合
ES2360164A1 (es) Ligandos de 5ht6 en el aumento de peso inducido por fármacos.
TW202131917A (zh) 併用醫藥
BRPI0710291A2 (pt) combinações de agente terapêuticos para tratamento de cáncer
CN1568189A (zh) 用于治疗疼痛的[[2－(氨基－3,4－二氧代－1－环丁烯－1－基)氨基]烷基]－酸衍生物
US20220162200A1 (en) Pkm2 modulators and methods for their use
JP4429732B2 (ja) 癌の処置におけるグリベック（ｓｔｉ５７１）とサイクリン依存性キナーゼインヒビター、とりわけフラボピリドールとの組合せ剤
CZ20032341A3 (cs) Použití antagonistů GAL3 receptoru pro léčbu deprese a/nebo úzkosti
US20080200489A1 (en) Combination of Organic Compounds
JP7130180B2 (ja) 子宮内膜症の処置のためのインドールの新規誘導体
RU2415134C2 (ru) Способ лечения или профилактики физиологических и/или патофизиологических состояний, опосредуемых рецепторами, стимулирующими секрецию гормона роста, триазолы и фармацевтическая композиция на их основе
JP2017531035A (ja) 非イオン性界面活性剤を有するアスピリン、メトホルミン及びセロトニンを含む医薬組成物
HK40019187A (en) Compounds for modulating s1p1 activity and methods of using the same
CN101198253A (zh) 治疗癌症的组合、方法和组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180511

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180709

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20180810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190423